{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:17:47Z","timestamp":1776133067330,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00280-018-3736-z","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T10:30:27Z","timestamp":1545129027000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome"],"prefix":"10.1007","volume":"83","author":[{"given":"Hirotoshi","family":"Iihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"3736_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1023\/A:1008270717294","volume":"8","author":"ML Rothenberg","year":"1997","unstructured":"Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann Oncol 8:837\u2013855","journal-title":"Ann Oncol"},{"key":"3736_CR2","first-page":"2175","volume":"18","author":"A Kono","year":"1991","unstructured":"Kono A, Hara Y (1991) Conversion of CPT-11 into SN-38 in human tissues. Gan To Kagaku Ryoho 18:2175\u20132178","journal-title":"Gan To Kagaku Ryoho"},{"key":"3736_CR3","first-page":"899","volume":"6","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Matsumoto K (1991) Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Gan To Kagaku Ryoho 6:899\u2013907","journal-title":"Gan To Kagaku Ryoho"},{"key":"3736_CR4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","volume":"65","author":"L Iyer","year":"1999","unstructured":"Iyer L, Hall D, Das S, Mortell MA, Ram\u00edrez J, Kim S, Di Rienzo A, Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576\u2013582","journal-title":"Clin Pharmacol Ther"},{"key":"3736_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1248\/yakushi.128.575","volume":"128","author":"K Sai","year":"2008","unstructured":"Sai K, Sawada J, Minami H (2008) Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28. Yakugaku Zasshi 128:575\u2013584","journal-title":"Yakugaku Zasshi"},{"key":"3736_CR6","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","volume":"102","author":"T Satoh","year":"2011","unstructured":"Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868\u20131873","journal-title":"Cancer Sci"},{"key":"3736_CR7","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"3736_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497\u2013504","journal-title":"Pharmacogenet Genom"},{"key":"3736_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D, Chabot GG, Armand JP, H\u00e9rait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210\u2013221","journal-title":"J Clin Oncol"},{"key":"3736_CR10","first-page":"34","volume":"23","author":"P Rougier","year":"1996","unstructured":"Rougier P, Bugat R (1996) CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23:34\u201341","journal-title":"Semin Oncol"},{"key":"3736_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1067\/mcp.2002.121909","volume":"71","author":"C Blandizzi","year":"2002","unstructured":"Blandizzi C, Danesi R, De Paolis B, Di Paolo A, Colucci R, Falcone A, Del Tacca M (2002) Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther 71:263\u2013271","journal-title":"Clin Pharmacol Ther"},{"key":"3736_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1124\/mol.56.6.1346","volume":"56","author":"HM Dodds","year":"1999","unstructured":"Dodds HM, Rivory LP (1999) The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 56:1346\u20131353","journal-title":"Mol Pharmacol"},{"key":"3736_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.bjp.0703766","volume":"132","author":"C Blandizzi","year":"2001","unstructured":"Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, Del Tacca M (2001) Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 132:73\u201384","journal-title":"Br J Pharmacol"},{"key":"3736_CR14","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752\u20133757","journal-title":"Cancer Res"},{"key":"3736_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.12788\/jcso.0099","volume":"13","author":"C Cheng","year":"2015","unstructured":"Cheng C, Lau JE, Earl MA (2015) Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome. J Community Support Oncol 13:3\u20137","journal-title":"J Community Support Oncol"},{"key":"3736_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00384-004-0613-5","volume":"19","author":"PF Yumuk","year":"2004","unstructured":"Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M, Karamanoglu A, Sengoz M, Turhal SN (2004) The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Int J Colorectal Dis 19:609\u2013610","journal-title":"Int J Colorectal Dis"},{"key":"3736_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1200\/JCO.2000.18.1.237","volume":"18","author":"G Zampa","year":"2000","unstructured":"Zampa G, Magnolfi E, Borgomastro A (2000) Premedication for irinotecan. J Clin Oncol 18:237","journal-title":"J Clin Oncol"},{"key":"3736_CR18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2165\/00003495-200767090-00007","volume":"67","author":"GN Tytgat","year":"2007","unstructured":"Tytgat GN (2007) Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67:1343\u20131357","journal-title":"Drugs"},{"key":"3736_CR19","first-page":"535","volume":"4","author":"E Robenshtok","year":"2002","unstructured":"Robenshtok E, Luria S, Tashma Z, Hourvitz A (2002) Adverse reaction to atropine and the treatment of organophosphate intoxication. Isr Med Assoc J 4:535\u2013539","journal-title":"Isr Med Assoc J"},{"key":"3736_CR20","first-page":"27","volume":"186","author":"H Deuren Van","year":"1979","unstructured":"Van Deuren H, Missotten L (1979) Atropine intoxication and the acute delirium of the elderly blind patient. Bull Soc Belge Ophtalmol 186:27\u201329","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"3736_CR21","first-page":"2236","volume":"6","author":"HC Pitot","year":"2000","unstructured":"Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236\u20132244","journal-title":"Clin Cancer Res"},{"key":"3736_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12032-018-1142-3","volume":"35","author":"Y Kanbayashi","year":"2018","unstructured":"Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Tabuchi Y, Kawano R, Yoshioka T, Yoshida N, Hosokawa T, Takayama K, Taguchi T (2018) Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. Med Oncol 35:82","journal-title":"Med Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3736-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:08:25Z","timestamp":1576609705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3736"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3736-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Yoshida has received grants, personal fees, and nonfinancial support from Chugai Pharmaceutical Co., Ltd. during the conduction of this study; grants and personal fees from Taiho Pharmaceutical Co., Ltd.; grants and personal fees from Pfizer Inc.; grants and personal fees from Yakult Honsha Co., Ltd.; grants from Bristol-Myers Squibb; grants from Kyowa Hakko Kirin Co., Ltd., outside the submitted work; and honoraria from Taiho Pharmaceutical Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Yakult Honsha Co., Ltd.; and had a consultant or advisory relationship with Taiho Pharmaceutical Co., Ltd. and La Roche, Ltd. T. Takahashi has received honoraria for lectures from Takeda Pharmaceutical Co., Ltd. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}